IGF1R and lung carcinoma: Since pre-clinical studies may contribute to the decision-making process for advancing these therapies to clinical trials, various pre-clinical studies have investigated IGF-1R-targeted therapies in lung cancer models, using monoclonal antibodies and tyrosine kinase inhibitors (Table 1).